Shares of PURE Bioscience (NASDAQL PURE) are falling this morning by 6.45%, trading at $2.61, after the company reported a $0.05 per share loss for the fourth quarter.
Notably, total revenues, which includes licensing fees, increased...(
read more)
PURE Bioscience engages in the development and commercialization of silver ion bioscience technologies principally in the United States. The company offers silver dihydrogen...(
read more)